Centrally Reduced Diffusion Sign for Differentiation between Treatment-Related Lesions and Glioma Progression: A Validation Study

References

1. 1.↵
   1. Stupp R,
   2. Mason WP,
   3. van den Bent MJ, et al

   . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 doi:10.1056/NEJMoa043330 pmid:5758009

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Alexiou GA,
   2. Zikou A,
   3. Tsiouris S, et al

   . Comparison of diffusion tensor, dynamic susceptibility contrast MRI and 99mTc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma. Magn Reson Imaging 2014;32:854–59 doi:10.1016/j.mri.2014.04.013 pmid:24848292

   CrossRefPubMed
3. 3.↵
   1. Asao C,
   2. Korogi Y,
   3. Kitajima M, et al

   . Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005;26:1455–60 pmid:15956515

   Abstract/FREE Full Text
4. 4.↵
   1. Ceschin R,
   2. Kurland BF,
   3. Abberbock SR, et al

   . Parametric response mapping of apparent diffusion coefficient as an imaging biomarker to distinguish pseudoprogression from true tumor progression in peptide-based vaccine therapy for pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2015;36:2170–76 doi:10.3174/ajnr.A4428 pmid:26338910

   Abstract/FREE Full Text
5. 5.↵
   1. Hein PA,
   2. Eskey CJ,
   3. Dunn JF, et al

   . Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201–09 pmid:14970018

   Abstract/FREE Full Text
6. 6.↵
   1. Lee WJ,
   2. Choi SH,
   3. Park CK, et al

   . Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. Acad Radiol 2012;19:1353–61 doi:10.1016/j.acra.2012.06.011 pmid:22884399

   CrossRefPubMed
7. 7.↵
   1. Matsusue E,
   2. Fink JR,
   3. Rockhill JK, et al

   . Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010;52:297–306 doi:10.1007/s00234-009-0613-9 pmid:19834699

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Prager AJ,
   2. Martinez N,
   3. Beal K, et al

   . Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 2015;36:877–85 doi:10.3174/ajnr.A4218 pmid:25593202

   Abstract/FREE Full Text
9. 9.↵
   1. Zhang H,
   2. Ma L,
   3. Shu C, et al

   . Diagnostic accuracy of diffusion MRI with quantitative ADC measurements in differentiating glioma recurrence from radiation necrosis. J Neurol Sci 2015;351:65–71 doi:10.1016/j.jns.2015.02.038 pmid:25748965

   CrossRefPubMed
10. 10.↵
    1. Zakhari N,
    2. Taccone MS,
    3. Torres C, et al

    . Diagnostic accuracy of centrally restricted diffusion in the differentiation of treatment-related necrosis from tumor recurrence in high-grade gliomas. AJNR Am J Neuroradiol 2018;39:260–64 doi:10.3174/ajnr.A5485 pmid:29217742

    Abstract/FREE Full Text
11. 11.↵
    1. Atlas SW,
    2. Dubois P,
    3. Singer MB, et al

    . Diffusion measurements in intracranial hematomas: Implications for MR imaging of acute stroke. AJNR Am J Neuroradiol 2000;21:1190–94 pmid:10954267

    Abstract/FREE Full Text
12. 12.↵
    1. Alcaide-Leon P,
    2. Luks TL,
    3. Lafontaine M, et al

    . Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. J Neurooncol 2020;146:71–73 doi:10.1007/s11060-019-03336-3 pmid:31728884

    CrossRefPubMed
13. 13.↵
    1. Wang S,
    2. Sakai Y,
    3. Chawla S, et al

    . Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 2016;37:28–36 doi:10.3174/ajnr.A4474 pmid:26450533

    Abstract/FREE Full Text
14. 14.↵
    1. Cohen J

    . A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37–46 doi:10.1177/001316446002000104

    CrossRefWeb of Science
15. 15.↵
    1. Cohen J

    . Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213–20 doi:10.1037/h0026256 pmid:19673146

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Bobek-Billewicz B,
    2. Stasik-Pres G,
    3. Majchrzak H, et al

    . Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 2010;48:81–92 pmid:20602289

    PubMedWeb of Science
18. 18.↵
    1. Wang S,
    2. Chen Y,
    3. Lal B, et al

    . Evaluation of radiation necrosis and malignant glioma in rat models using diffusion tensor MR imaging. J Neurooncol 2012;107:51–60 doi:10.1007/s11060-011-0719-x pmid:21948114

    CrossRefPubMed